Loading clinical trials...
Loading clinical trials...
A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR). Almost all of those complications are characterized by an elevation in liver enzymes (ALT, AST and GGT) and a decline of liver function tests (serum bilirubin and INR increase) possibly leading to early allograft disfunction (EAD). In this scenario there is a lack of biomarker that could predict the development of ACR and/or EAD. The aim of this study is to explore the prognostic role of non-invasive instrumental and biological marker in the early post-transplant phase.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, Italy
Start Date
July 6, 2020
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2027
Last Updated
March 31, 2023
100
ESTIMATED participants
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT03193151
NCT06950788
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04234139